[Form 4] AdaptHealth Corp. Insider Trading Activity

Rhea-AI Filing Summary

SEC Form 4 filed on 06/30/2025 shows AdaptHealth Corp. (AHCO) director Gregory Belinfanti acquired a total of 28,086 common shares on 06/26/2025 through two transactions recorded at $0.00 per share, indicating stock awards rather than open-market purchases. His direct holdings rose from an estimated 45,408 shares to 73,494 shares after the grants. No derivative securities were reported. While the amount is modest relative to AHCO’s float, the additional ownership slightly tightens insider–shareholder alignment and is typically viewed as a mildly positive governance signal.

Positive

• Director increased direct share ownership by 28,086 shares, modestly enhancing management–shareholder alignment.

Negative

• None.

Insights

Securities Analyst

TL;DR – Routine stock grants raise director’s stake by 28k; alignment positive but valuation impact negligible.

The filing reflects standard board compensation rather than discretionary buying. The zero-cost entries point to restricted stock or similar awards, not cash outlay, so no pricing signal exists. Post-grant ownership of 73,494 shares remains well below 1 % of shares outstanding, limiting any influence on control or liquidity. Investors may take modest comfort in added skin-in-the-game, yet the transaction does not materially change AdaptHealth’s capital structure or earnings outlook, leaving the overall impact neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BELINFANTI GREGORY

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AENUE, 19TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AdaptHealth Corp. [ AHCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		A		21,346	A	$0	66,754	D
Common Stock	06/26/2025		A		6,740	A	$0	73,494	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Richard Rew, as attorney-in-fact for Gregory Belinfanti	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many AdaptHealth (AHCO) shares did director Gregory Belinfanti acquire on 06/26/2025?

He received 28,086 common shares in two separate grants on 06/26/2025.

What is Gregory Belinfanti’s total AHCO ownership after the reported transactions?

Following the grants, Belinfanti directly owns 73,494 AHCO shares.

Were the shares purchased or granted, and at what price?

The shares were granted at $0.00 per share, indicating equity compensation rather than open-market purchases.

Does this Form 4 include any derivative securities transactions?

No. The filing lists no options, warrants, or other derivative securities activity.

Why should investors care about a Form 4 filing for AHCO?

Form 4 filings reveal insider trades or grants. Added ownership can signal confidence or alignment, though materiality depends on stake size.